Gamma Vaccines is focused on developing innovative vaccines aimed at preventing viral infections in both humans and animals. The company utilizes proprietary technologies that were initially developed in collaboration with leading Australian universities. These technologies are designed to induce broad-spectrum immune responses against significant viral pathogens, thereby addressing the need for effective vaccines that can reduce the incidence of viral diseases and mitigate the risk of pandemic outbreaks.

In addition to its foundational technologies, Gamma Vaccines is actively expanding its portfolio through strategic collaborations. Recently, the company acquired intellectual property rights to develop a vaccine for Newcastle disease, which highlights its commitment to advancing vaccine solutions. Furthermore, Gamma Vaccines has entered into an international collaboration with Capricorn Technologies and Aptum Adjuvants to enhance vaccine effectiveness by integrating their innovative approaches with Gamma Vaccines' manufacturing technology. This collaborative effort underscores the company's dedication to scientific excellence and global health solutions.

Australia

Gamma Vaccines Pty is a biotechnology company that specializes in developing a 'universal' cross-protective influenza virus vaccine called Gamma-Flu®.

Gamma Vaccines

Company Details